Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 8 · below the Ichimoku cloud · RSI 29 (oversold) · MACD above its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.6M | 0.00% | 73.59K | −46% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a JBIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 11, 2026 | Dahms Bradford DChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 37.8K | — |
| Feb 11, 2026 | Frohlich TomChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 78.8K | — |
| Feb 11, 2026 | King Andrew JamesOfficer | Stock Award(Grant) at price 0.00 per share. | 41.3K | — |
| Feb 11, 2026 | Balta ElizabethOfficer | Stock Award(Grant) at price 0.00 per share. | 28.1K | — |
| Oct 5, 2025 | Fairmount Funds Management LlcBeneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 9.14 per share. | 1.33M | $12.18M |
| May 15, 2025 | Frohlich TomChief Executive Officer | Purchase at price 7.40 per share. | 6K | $44.40K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.2 | -5.0 | -5.3 | 73.7 | -13.8 | 5.6 | -11.1 | 8.2 | -34.2 | -4.5 | −13.0% | ||
| 2025 | -1.1 | -7.3 | 3.3 | -89.2 | -23.7 | 37.8 | -28.0 | 9.9 | 9.2 | 13.6 | 30.8 | 20.4 | −83.4% |
| 2024 | -14.7 | 19.5 | 28.1 | -32.3 | -12.8 | -90.5 | 9.6 | 6.0 | 8.3 | 17.2 | 7.3 | 0.8 | −88.3% |
| 2023 | -22.0 | 7.5 | -17.9 | 4.0 | -22.5 | 5.5 | 1.7 | -8.9 | -14.6 | -21.8 | 48.1 | 44.0 | −22.8% |
| 2022 | 0.3 | -17.3 | 87.4 | -30.4 | -4.7 | 28.6 | 42.4 | -10.9 | -16.4 | 17.7 | -3.4 | 55.5 | +148.5% |
| 2021 | -43.7 | 33.0 | 22.8 | -24.1 | -13.9 | -14.0 | −48.4% |
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Buy / hold / sell counts